相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension ASA-STAT
Steven M. Kawut et al.
CIRCULATION (2011)
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
R. Dumitrascu et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension
W-T. N. Lee et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension
Robyn J. Barst et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2011)
Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy
Hossein A. Ghofrani et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Simvastatin as a Treatment for Pulmonary Hypertension Trial
M. R. Wilkins et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
Raymond L. Benza et al.
CIRCULATION (2010)
Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
Marc Humbert et al.
CIRCULATION (2010)
A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension
M. Gomberg-Maitland et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2010)
Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation
T. Thenappan et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
H. A. Ghofrani et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
M. Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil
K. T. B. Mouchaers et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension
Hiroshi Fujita et al.
HEART AND VESSELS (2010)
PRX-08066, a Novel 5-Hydroxytryptamine Receptor 2B Antagonist, Reduces Monocrotaline-Induced Pulmonary Arterial Hypertension and Right Ventricular Hypertrophy in Rats
Stacy L. Porvasnik et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension A Randomized Controlled Clinical Trial
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
RhoA and Rho Kinase Activation in Human Pulmonary Hypertension Role of 5-HT Signaling
Christophe Guilluy et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
Michael D. McGoon et al.
CHEST (2009)
Tadalafil Therapy for Pulmonary Arterial Hypertension
Nazzareno Galie et al.
CIRCULATION (2009)
Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
A. Lavelle et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension
M. M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
B. Degano et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Guidelines for the diagnosis and treatment of pulmonary hypertension
N. Galie et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
Ronald J. Oudiz et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Diagnosis and Assessment of Pulmonary Arterial Hypertension
David B. Badesch et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
H. A. Ghofrani et al.
EUROPEAN RESPIRATORY REVIEW (2009)
Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats
Xiaowei Sun et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension
Frederic Perros et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Hypoxia during air travel in adults with pulmonary disease
Lawrence C. Mohr
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2008)
The Vasoactive Intestinal Peptide Gene Is a Key Modulator of Pulmonary Vascular Remodeling and Inflammation
Sami I. Said
Neural Signaling: Opportunities for Novel Diagnostic Approaches and Therapies (2008)
Pulmonary hypertension: therapeutic targets within the serotonin system
Y. Dempsie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics
Ming Hui Chen et al.
CIRCULATION (2008)
Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Nazzareno Galie et al.
CIRCULATION (2008)
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Christian F. Opitz et al.
EUROPEAN HEART JOURNAL (2008)
Pulmonary arterial hypertension associated with fenfluramine exposure:: report of 109 cases
R. Souza et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Inhalation of vasoactive intestinal peptide in pulmonary hypertension
H. H. Leuchte et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension
R. T. Schermuly et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Bloodstream infections in patients given treatment with intravenous prostanoids
Alexander J. Kallen et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2008)
A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2yl)(isopropyl) amino]butoxy}-N-(methylsulfonyl)acetamide(NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy} acetic acid (MRE-269), on rat pulmonary artery
Keiichi Kuwano et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist
Marc Iglarz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):: a double-blind, randomised controlled trial
N. Galie et al.
LANCET (2008)
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension
Liliana Moreno-Vinasco et al.
PHYSIOLOGICAL GENOMICS (2008)
Experience with inhaled iloprost and bosentan in portopulmonary hypertension
M. M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists
Tetsuo Asaki et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug
Keiichi Kuwano et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Results of European post-marketing surveillance of bosentan in pulmonary hypertension
M. Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
An epidemiological study of pulmonary arterial hypertension
A. J. Peacock et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension - A pilot randomized controlled trial
Xing-Gang Wang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension
Marcin Kurzyna et al.
CHEST (2007)
Combination therapy and new types of agents for pulmonary arterial hypertension
Dermot O'Callaghan et al.
CLINICS IN CHEST MEDICINE (2007)
Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension
Richard N. Channick et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension
Derliz Mereles et al.
CIRCULATION (2006)
Long term imatinib treatment in pulmonary arterial hypertension
R. Souza et al.
THORAX (2006)
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkela et al.
NATURE MEDICINE (2006)
Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension
Karen C. Patterson et al.
ANNALS OF INTERNAL MEDICINE (2006)
Bosentan therapy in patients with Eisenmenger syndrome - A multicenter, double-blind, randomized, placebo-controlled study
Nazzareno Galie et al.
CIRCULATION (2006)
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
Robyn J. Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Pulmonary arterial hypertension in France - Results from a national registry
M Humbert et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension
S Provencher et al.
GASTROENTEROLOGY (2006)
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential
Oleg V. Evgenov et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension
M Gomberg-Maitland et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
O Sitbon et al.
THORAX (2005)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
MM Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Reversal of experimental pulmonary hypertension by PDGF inhibition
RT Schermuly et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Imatinib for the treatment of pulmonary arterial hypertension
HA Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension
CF Opitz et al.
EUROPEAN HEART JOURNAL (2005)
Effects of long-term bosentan in children with pulmonary arterial hypertension
EB Rosenzweig et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Ambrisentan therapy for pulmonary arterial hypertension
N Galié et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
O Sitbon et al.
CIRCULATION (2005)
Severe pulmonary hypertension during pregnancy -: Mode of delivery and anesthetic management of 15 consecutive cases
M Bonnin et al.
ANESTHESIOLOGY (2005)
Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension
KA Reisbig et al.
ANNALS OF PHARMACOTHERAPY (2005)
Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells - Efficacy of combined cell and eNOS gene therapy in established disease
YDD Zhao et al.
CIRCULATION RESEARCH (2005)
Bosentan therapy for portopulmonary hypertension
MM Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Survival with first-line bosentan in patients with primary pulmonary hypertension
VV McLaughlin et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Sitaxsentan therapy for pulmonary arterial hypertension
RJ Barst et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Drug therapy: Treatment of pulmonary arterial hypertension
M Humbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
被撤回的出版物: Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells (Retracted article. See vol. 1812, pg. 1200, 2011)
T Kato et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2004)
Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin®) administered by the intravenous and subcutaneous route to normal volunteers
K Laliberte et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2004)
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension
O Sitbon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension
H Olschewski et al.
CHEST (2003)
Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells
T Nishimura et al.
CIRCULATION (2003)
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension - A 1-year follow-up study
O Sitbon et al.
CHEST (2003)
Beraprost therapy for pulmonary arterial hypertension
RJ Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Assessment of the vasodilator response in primary pulmonary hypertension - Comparing prostacyclin and iloprost administered by either infusion or inhalation
CF Opitza et al.
EUROPEAN HEART JOURNAL (2003)
Survival in primary pulmonary hypertension - The impact of epoprostenol therapy
VV McLaughlin et al.
CIRCULATION (2002)
Inhaled iloprost for severe pulmonary hypertension
H Olschewski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension:: With pulmonary arterial hypertension:: A randomized, double-blind, placebo-controlled trial
N Galiè et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension - A double-blind, randomized, placebo-controlled trial
G Simonneau et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
RN Channick et al.
LANCET (2001)
分享论文
